Loading...
Market
How many countries will approve lenacapavir by end of 2025?
2
Resolution / Starting Odds
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Regulatory approval announcements from health authorities in the respective countries
Story
Gilead Signs Royalty-Free Deals with Six Generics for Investigational HIV Drug Lenacapavir in 120 Countries
Oct 2, 2024, 01:35 PM
Gilead Sciences has signed non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers, including Dr. Reddy's Laboratories and Hetero, to enable access to its investigational HIV prevention medication, lenacapavir, across 120 high-incidence, resource-limited countries. Lenacapavir, pending regulatory approval, is a twice-yearly injectable drug used for HIV-1 prevention and treatment in heavily treatment-experienced adults. The agreements aim to increase global access to this groundbreaking medication, accelerating the global HIV response.
View original story
Similar markets
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 50 • 25%
50 to 80 • 25%
81 to 120 • 25%
More than 120 • 25%
United States • 25%
European Union • 25%
South Africa • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%